Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With ... (PR Newswire via Yahoo! Finance) PDF Print

Researchers today report that after the implementation of Medicare coverage limitations for erythropoiesis-stimulating agents , a significantly greater proportion of anemic cancer patients who were on chemotherapy and who received ESAs needed blood transfusions and utilized more units of blood per patient than those patients who received ESAs prior to implementation of coverage limitations.

read more

 
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.